8-K: BioSig Technologies Faces Delisting from Nasdaq Despite Appeal Efforts

BioSig Technologies' appeal to reconsider its delisting from Nasdaq was declined, and the company is now seeking to trade on the OTC Markets OTCQB platform while pursuing a further appeal.

Summary

• BioSig Technologies was notified on June 24, 2024, that Nasdaq declined to reconsider its decision to delist the company's common stock.
• Trading of BioSig's stock on Nasdaq was suspended on June 12, 2024, and it became eligible to trade on the OTC Markets Pink Current Information tier.
• The company is currently seeking approval to trade on the OTC Markets OTCQB platform.
• BioSig has appealed the delisting decision to the Nasdaq Listing and Hearing Review Council on June 25, 2024, in an attempt to maintain its Nasdaq listing.
• The company plans to provide updates on the appeal process as significant events occur.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event with the delisting from Nasdaq, despite the company's efforts to appeal and move to the OTC markets. This suggests a challenging period for the company.

Positives

• BioSig is actively seeking to trade on the OTC Markets OTCQB platform.
• The company has appealed the delisting decision to the Nasdaq Listing and Hearing Review Council.

Negatives

• Nasdaq declined to reconsider its decision to delist BioSig Technologies' common stock.
• Trading of BioSig's stock on Nasdaq was suspended.

Risks

• There is a risk that the appeal to the Nasdaq Listing and Hearing Review Council will be unsuccessful.
• The company's stock is currently trading on the OTC Markets Pink Current Information tier, which may have lower trading volumes and less visibility than Nasdaq.
• There is no guarantee that the company will be approved to trade on the OTC Markets OTCQB platform.

Future Outlook

The company plans to provide updates regarding the appeal effort as material events occur.

Management Comments

• The company is seeking approval for its common stock to trade on the OTC Markets OTCQB trading platform.
• The company is appealing the delisting decision to the Nasdaq Listing and Hearing Review Council in an effort to maintain the company's listing on Nasdaq.

Industry Context

Delisting from a major exchange like Nasdaq can negatively impact a company's visibility and investor confidence, often leading to lower trading volumes and potentially affecting the company's ability to raise capital. Companies in this situation often seek to trade on alternative markets like the OTC Markets.

Comparison to Industry Standards

• Companies facing delisting from major exchanges often experience a decline in stock price and trading volume.
• Moving to the OTC Markets is a common step for companies that have been delisted from Nasdaq or the NYSE.
• The success of an appeal to maintain a listing varies, and the outcome is uncertain.

Stakeholder Impact

• Shareholders may experience a decrease in the value of their investment due to the delisting.
• The company's ability to raise capital may be affected by the delisting.
• Employees may be concerned about the company's future prospects.

Next Steps

• BioSig will await the outcome of its appeal to the Nasdaq Listing and Hearing Review Council.
• The company will seek approval to trade on the OTC Markets OTCQB platform.
• BioSig will provide updates on the appeal process as material events occur.

Key Dates

Keywords

delisting, Nasdaq, OTC Markets, BSGM, stock, appeal, trading, OTCQB, Pink Current Information